製品の概要

  • 製品名Anti-TACI antibody [1A1]
    TACI 一次抗体 製品一覧
  • 製品の詳細
    Rat monoclonal [1A1] to TACI
  • アプリケーション適用あり: Flow Cytmore details
  • 種交差性
    交差種: Human
  • 免疫原

    Tissue/ cell preparation (Human) - human TACI transfected into rat RBL cells.

  • ポジティブ・コントロール
    • Blood B cells.

製品の特性

  • 製品の状態Liquid
  • 保存方法Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C or -80°C. Avoid freeze / thaw cycle.
  • Concentration information loading...
  • 精製度Protein G purified
  • ポリ/モノモノクローナル
  • クローン名1A1
  • ミエローマSp2/0
  • アイソタイプIgG2a
  • 研究分野

アプリケーション

Our Abpromise guarantee covers the use of ab16230 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

アプリケーション Abreviews 特記事項
Flow Cyt Use a concentration of 5 µg/ml. Levels or Taci are variable and often low in human blood.



ab18450-Rat monoclonal IgG2a, is suitable for use as an isotype control with this antibody.

ターゲット情報

  • 機能Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T-cell function and the regulation of humoral immunity.
  • 組織特異性Highly expressed in spleen, thymus, small intestine and peripheral blood leukocytes. Expressed in resting B-cells and activated T-cells, but not in resting T-cells.
  • 関連疾患Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2) [MIM:240500]. CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B cells is usually in the normal range, but can be low.
    Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2) [MIM:609529]. Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology.
  • 配列類似性Contains 2 TNFR-Cys repeats.
  • 細胞内局在Membrane.
  • Information by UniProt
  • 参照データベース
  • 別名
    • CD 267 antibody
    • CD267 antibody
    • CD267 antigen antibody
    • CVID antibody
    • CVID2 antibody
    • FLJ39942 antibody
    • MGC133214 antibody
    • MGC39952 antibody
    • OTTHUMP00000065442 antibody
    • TNFRSF 13B antibody
    • TNFRSF 14B antibody
    • TNFRSF13B antibody
    • TNFRSF13B protein antibody
    • TNFRSF14B antibody
    • TR13B_HUMAN antibody
    • Transmembrane activator and CAML interactor antibody
    • Tumor necrosis factor receptor 13B antibody
    • Tumor necrosis factor receptor superfamily member 13B antibody
    see all

Anti-TACI antibody [1A1] (ab16230) 使用論文

This product has been referenced in:
  • Schwaller J  et al. Neutrophil-derived APRIL concentrated in tumor lesions by proteoglycans correlates with human B-cell lymphoma aggressiveness. Blood 109:331-8 (2007). Read more (PubMed: 17190854) »
  • Salzer U  et al. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet 37:820-8 (2005). Read more (PubMed: 16007087) »

See all 3 Publications for this product

Product Wall

Thank you for your enquiry. According to our records there were some quality issues around this time that led to the removal of various applications although the application of FACS by this antibody was not questioned. However, I am prepared to o...

Read More

I'm sorry to hear the customer is experiencing problems in FACS with some of our antibodies, it is likely that the problem is protocol related. I have received this morning a detailed FACS protocol with details of the buffers to use and fixative to use...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"